Muscarinic receptors are a family of five proteins (labeled M1 through M5) that sit on the surface of cells throughout your body and respond to acetylcholine, a chemical messenger involved in everything from thought and memory to heartbeat and digestion. They belong to the large superfamily of G-protein coupled receptors, meaning they relay signals not by opening a channel in the cell membrane but by triggering a cascade of events inside the cell through intermediary G proteins.1IntechOpen. Central Nicotinic and Muscarinic Receptors in Health and Disease The five subtypes differ in where they are concentrated, which G proteins they activate, and what physiological effects they produce. Those differences have made them targets for drugs treating conditions as varied as chronic lung disease, overactive bladder, Alzheimer’s disease, and schizophrenia.
How Muscarinic Receptors Differ from Nicotinic Receptors
Acetylcholine acts through two receptor classes. Nicotinic receptors are ion channels: when acetylcholine binds, the channel opens in milliseconds and ions rush across the membrane, producing a fast electrical signal. That is why nicotinic receptors handle the rapid-fire communication at nerve-muscle junctions. Muscarinic receptors work on a slower timescale. When acetylcholine binds a muscarinic receptor, the receptor changes shape and activates a G protein on the inside of the cell, which then sets off a chain of chemical signals. This slower, more sustained signaling is well suited to regulating processes like heart rate, glandular secretion, and the excitability of neurons in the brain.
Two Signaling Families Within the Five Subtypes
The five muscarinic subtypes split neatly into two camps based on the G protein they prefer. M1, M3, and M5 couple mainly to one family of G proteins (Gq/11), which triggers a cascade that raises calcium levels inside the cell and tends to be excitatory. M2 and M4 couple preferentially to a different family (Gi/o), which lowers the concentration of a signaling molecule called cyclic AMP and generally inhibits cellular activity.2PubMed Central. Understanding G Protein Selectivity of Muscarinic Acetylcholine Receptors Using Computational Methods This split explains why activating M2 receptors in the heart slows it down, while activating M3 receptors in the airways constricts smooth muscle.
The “preferentially” is important. Muscarinic receptors are not locked into a single signaling pathway. Research on M4 receptors, for instance, found that at low agonist concentrations the receptor reduces cyclic AMP as expected, but at higher concentrations it can actually increase cyclic AMP through a different G protein entirely.3PubMed Central. Downstream Signaling of Muscarinic M4 Receptors Is Regulated by Receptor Density and Cellular Environment How many receptors a cell carries and the cocktail of G proteins available inside it can shift the response. This flexibility complicates drug design but also opens the door to more precisely tuned therapies.
M1 Receptors and Cognition
M1 is the most abundant muscarinic subtype in the cerebral cortex and hippocampus, the brain regions most associated with learning and memory. Knockout mice that lack the M1 receptor show a revealing pattern: some memory tasks are performed normally or even better than usual, but working memory and the ability to consolidate new information are severely impaired, and long-term potentiation in the hippocampus (a cellular correlate of memory formation) is reduced.4Nature Neuroscience. Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice The selective nature of those deficits suggests that M1 is not a general “memory switch” but is specifically needed when the cortex and hippocampus must work together.
Aging-related memory decline has been tied to changes in cholinergic signaling, and M1 activation shows promise as a way to counteract those changes. In a mouse study, systemic activation of M1 receptors reversed age-related deficits in the ability to update existing object memories, with cellular analysis pointing to subtle changes in cholinergic markers in the perirhinal cortex that accumulate over the lifespan.5PubMed. M1 muscarinic receptor activation reverses age-related memory updating impairment in mice These findings are still in the animal-model stage, but they have helped drive drug development aimed at boosting M1 activity in humans with cognitive impairment.
M2 Receptors and the Heart
M2 is the dominant muscarinic subtype in cardiac tissue. Its best-known job is slowing the heart: when the vagus nerve releases acetylcholine onto the heart, M2 receptors reduce the rate at which electrical impulses pass through the atrioventricular node, producing the familiar resting heart rate that is well below the heart’s intrinsic firing rate.6PubMed Central. Muscarinic Receptors in Cardioprotection and Vascular Tone Regulation Without tonic vagal M2 stimulation, the heart beats considerably faster.
M2 also plays a crucial feedback role at nerve endings throughout the body. Presynaptic M2 receptors on cholinergic neurons sense how much acetylcholine is already floating around the synapse and, when levels get high, put the brakes on further release. This autoinhibition was demonstrated decades ago in experiments showing that muscarinic agonists reduce the calcium-dependent release of stored acetylcholine, an effect reversed by the muscarinic blocker atropine.7PubMed. Differential inhibition of the release of endogenous and newly synthesized acetylcholine from Torpedo synaptosomes Complementary work in rat airways confirmed that blocking these presynaptic receptors with scopolamine dramatically boosted acetylcholine release, underscoring how tightly the system polices itself.8PubMed. Presynaptic inhibition of acetylcholine release This feedback loop matters clinically because drugs that block M2 indiscriminately can inadvertently flood the synapse with extra acetylcholine, creating unintended stimulation elsewhere.
M3 Receptors in Smooth Muscle and Glands
M3 receptors are the workhorses of smooth-muscle contraction and glandular secretion outside the central nervous system. They line the airways, the gut wall, the bladder’s detrusor muscle, and the salivary glands. In the bladder, M3 is the receptor primarily responsible for the contraction that empties it.9PubMed Central. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder In the airways, M3 drives the constriction of bronchial smooth muscle and promotes mucus secretion. In the salivary glands, M3 stimulation is what makes your mouth water. Because M3 operates in so many organ systems simultaneously, blocking it to treat one organ’s problem often produces side effects in another. The dry mouth that plagues many overactive-bladder patients on antimuscarinics, for example, happens because the drug also blocks M3 receptors in the salivary glands.
M4 Receptors and Dopamine
M4 receptors are concentrated in the striatum and other brain areas where dopamine signaling is especially active. Research using knockout mice showed that losing M4 leads to elevated baseline dopamine levels in the nucleus accumbens and an exaggerated dopamine response to stimulant drugs, creating what the researchers described as a state of “dopaminergic hyperexcitability.”10PubMed. M4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related CNS pathologies In other words, M4 normally acts as a check on dopamine signaling. When that check is missing, the brain’s reward and motivation circuits run hotter than they should.
This connection has clear implications for schizophrenia, which involves excessive dopamine activity in certain brain circuits. It has also spurred interest in M4 as a drug target for conditions in which dampening dopamine would be therapeutic, an approach distinct from the traditional antipsychotics that block dopamine receptors directly.
M5 Receptors and Cerebral Blood Flow
M5 is the least abundant and last-discovered of the five subtypes. Its expression in the brain is limited, but it plays a disproportionate role in two specific areas: dopamine release in the striatum and dilation of blood vessels in the brain. Knockout experiments in mice revealed that acetylcholine, which normally powerfully dilates blood vessels, virtually lost its ability to widen cerebral arteries in animals lacking M5, while dilation of blood vessels outside the brain was completely unaffected.11PubMed Central. Cholinergic dilation of cerebral blood vessels is abolished in M(5) muscarinic acetylcholine receptor knockout mice That exquisite specificity for the brain’s vasculature has drawn attention to M5 as a possible target for conditions involving impaired cerebral blood flow, though no M5-selective drugs have reached the clinic yet.12PubMed. Use of M1-M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system
How Cells Dial Down the Response
Cells cannot afford to keep responding at full blast when muscarinic stimulation persists. They have evolved mechanisms to tone down, or “desensitize,” receptors that have been activated for too long. Work on the M2 receptor revealed that a specialized enzyme phosphorylates the receptor shortly after agonist binding, and this phosphorylation is necessary for the acute drop in responsiveness. Blocking that enzyme prevented desensitization even though the agonist was still present.13Journal of Biological Chemistry. Desensitization and Internalization of the m2 Muscarinic Acetylcholine Receptor Are Directed by Independent Mechanisms
Separately, the receptor gets physically pulled off the cell surface and packed into small intracellular bubbles called clathrin-coated vesicles. In cardiac cells exposed to a muscarinic agonist for two hours, roughly 83% of M2 receptors were internalized from the membrane.14PubMed. Role of internalization of M2 muscarinic receptor via clathrin-coated vesicles in desensitization of the muscarinic K+ current in heart Importantly, phosphorylation and internalization are driven by independent mechanisms; the receptor can be pulled inside the cell even when phosphorylation-driven desensitization is blocked. This two-layered system gives the cell both a fast way to mute the signal (phosphorylation) and a slower, more thorough way to remove the receptor from action entirely (internalization). The practical upshot is that prolonged drug exposure can reduce the very receptors the drug is meant to activate or block, which is one reason clinical effects sometimes wane over time.
Drugs That Target Muscarinic Receptors
Muscarinic pharmacology has historically been hampered by a frustrating problem: the five subtypes look almost identical in the pocket where acetylcholine binds, making it hard to design drugs that affect only one subtype.15PubMed Central. Muscarinic receptor antagonists, from folklore to pharmacology; finding drugs that actually work in asthma and COPD An older drug like atropine blocks all five subtypes and produces a laundry list of effects, from dilated pupils to rapid heart rate to constipation. Even modern drugs often hit multiple subtypes, which is why a medication prescribed for one organ system so often causes side effects in another.
The clearest success story is in lung disease. Long-acting muscarinic antagonists (LAMAs), such as tiotropium, glycopyrronium, and aclidinium, are a mainstay treatment for chronic obstructive pulmonary disease and are now increasingly used in asthma as well. These drugs preferentially block M3 receptors (which constrict the airways) and dissociate more slowly from M3 than from M2, meaning they open the airways without flooding the nerve terminals with extra acetylcholine.16PubMed Central. Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases Clinical evidence now supports their use as add-on therapy alongside inhaled corticosteroids and long-acting beta-agonists for people with moderate to severe asthma that remains poorly controlled on standard treatment.17PubMed. Understanding the role of long-acting muscarinic antagonists in asthma treatment
In overactive bladder, antimuscarinics like oxybutynin, solifenacin, and tolterodine work by blocking the M2 and M3 receptors in the detrusor muscle that drive unwanted contractions.18PubMed Central. Muscarinic receptors in the bladder: from basic research to therapeutics Newer agents like solifenacin were designed for higher selectivity at M3 in the bladder, aiming to reduce the dry mouth and cognitive effects associated with less selective drugs.19PubMed. Comparison of muscarinic receptor selectivity of solifenacin and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout mice Still, side effects remain a common reason patients stop taking these medications.
The New Wave of Subtype-Selective Brain Drugs
The most exciting recent development has been the shift toward “positive allosteric modulators,” or PAMs. Instead of binding in the same conserved pocket where acetylcholine sits (where all five subtypes look alike), PAMs bind to a different spot on the receptor that varies more between subtypes. This approach allows a drug to boost the activity of one subtype without directly activating it or interfering with others.
An M1 PAM called VU0467319, or VU319, has already completed a Phase I clinical trial in healthy volunteers. It enhanced M1 activity at modest potency, showed strong brain penetration across multiple animal species, and produced no cholinergic side effects in rats, dogs, or primates at therapeutic-range doses.20PubMed Central. Discovery of VU0467319: an M1 Positive Allosteric Modulator Candidate That Advanced into Clinical Trials On the M4 side, researchers recently identified a structurally novel PAM, VU6016235, which demonstrated low-nanomolar potency at human and rat M4, high brain penetration, and efficacy in a preclinical model of psychosis.21PubMed Central. Discovery of VU6016235: A Highly Selective, Orally Bioavailable, and Structurally Distinct Tricyclic M4 Muscarinic Acetylcholine Receptor Positive Allosteric Modulator (PAM) Neither compound is an approved treatment yet, but their progress reflects a broader push to exploit allosteric binding sites for subtype selectivity.
These allosteric strategies have been informed by high-resolution structures. Cryo-electron microscopy at near-atomic resolution revealed, for example, that the drug xanomeline simultaneously occupies both the standard binding pocket and a second “allosteric” site on the M4 receptor, a dual-occupancy mode that had not been anticipated.22Nature Communications. Xanomeline displays concomitant orthosteric and allosteric binding modes at the M4 mAChR A separate cryo-EM study of M5 uncovered an allosteric pocket at a completely different location, between two of the receptor’s transmembrane segments, offering yet another druggable surface.23PubMed Central. Cryo-EM reveals an extrahelical allosteric binding site at the M5 mAChR These structural revelations are changing how chemists think about designing selective muscarinic drugs.
Muscarinic Receptors in Alzheimer’s Disease and Schizophrenia
The cholinergic system has been implicated in Alzheimer’s disease for decades, and muscarinic receptors have been a recurring drug target. The first large-scale placebo-controlled trial of a direct muscarinic agonist, xanomeline, showed improvements in both cognitive scores and behavioral symptoms in Alzheimer’s patients, providing the earliest clinical proof that directly stimulating muscarinic receptors could help.24PubMed. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease The catch was peripheral side effects: nausea, sweating, and gastrointestinal distress from activating muscarinic receptors in the gut and glands. Those side effects stalled xanomeline’s development for years.
More recently, researchers paired xanomeline with trospium chloride, an antimuscarinic drug that does not cross the blood-brain barrier. The idea is elegant: trospium mops up the peripheral muscarinic activation while leaving the brain effects intact. This combination (marketed as KarXT) has been tested in schizophrenia, where converging evidence points to M1 and M4 as important therapeutic targets partly because of their interactions with glutamate circuits that are disrupted in the disease.25International Journal of Neuropsychopharmacology. From theory to therapy: unlocking the potential of muscarinic receptor activation in schizophrenia with the dual M1/M4 muscarinic receptor agonist xanomeline and trospium chloride and insights from clinical trials This represents the first fundamentally new mechanism for treating schizophrenia in decades, moving beyond the dopamine-receptor blockade that has defined antipsychotics since the 1950s.
An Ancient Signaling System
Muscarinic receptors appear to be an invention of the bilaterians, the branch of animal life that includes everything from insects to humans. Analyses of gene sequences across the animal kingdom find no muscarinic receptors in cnidarians such as jellyfish and sea anemones, placing the origin of these receptors after the split between radially symmetric and bilaterally symmetric animals roughly 700 million years ago.26PubMed Central. Two types of muscarinic acetylcholine receptors in Drosophila and other arthropods
In vertebrates, the five subtypes arose through two rounds of whole-genome duplication early in vertebrate evolution. One ancestral gene gave rise to what became M2 and M4, and the other produced M1, M3, and M5.27PubMed Central. Evolution of the Muscarinic Acetylcholine Receptors in Vertebrates This ancestry is reflected in the signaling split described earlier: the M2/M4 pair both couple to inhibitory G proteins, while the M1/M3/M5 trio all couple to excitatory ones. All five genes have been retained across nearly every vertebrate lineage examined, with the curious exception that M1 has been lost in chickens and some other birds. Zebrafish, which experienced an additional round of genome duplication, carry duplicates of all five, giving them ten muscarinic receptor genes in total.27PubMed Central. Evolution of the Muscarinic Acetylcholine Receptors in Vertebrates The remarkable conservation of these five subtypes across hundreds of millions of years of vertebrate evolution underscores how essential each one’s particular function has been, and why losing even one (as birds apparently did with M1) is the exception rather than the rule.